Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 7-11

  Meng, Maxwell V ^a,b   Grossfeld, Gary D ^a   Sadetsky, Natalia ^b   Mehta, Shilpa S ^c   Lubeck, Deborah P ^b   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TAP Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RISK; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY;

EID: 18644367900     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01560-1     Document Type: Article

References (19)

1. Huggins C.B., Hodges R.A. Studies on prostate cancer the effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res. 1:1941;293-297.
2. Huggins C., Stephens R.C., Hodges C.V. Studies on prostatic cancer the effects of castration on advanced carcinoma of the prostate gland . Arch Surg. 43:1941;209-213.
3. Goharderakhshan R.Z., Grossfeld G.D., Kassis A., et al. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. Urology. 56:2000;622-626.
4. Cher M.L., Shinohara K., Breslin S., et al. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer. Br J Urol. 75:1995;771-777.
5. Abbas F., Scardino P.T. Why neoadjuvant deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am. 23:1996;587-604.
6. Schulman C.C., Debruyne F.M.J., Forster G., et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol. 38:2000;706-713.
7. Vailancourt L., Tetu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol. 20:1996;86-93.
8. Soloway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 154:1995;424-428.
9. Dalkin B.L., Ahmann F.R., Nagle R., et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 155:1996;1357-1360.
10. Aus G., Abrahamsson P.-A., Ahlgren G., et al. Hormonal treatment before radical prostatectomy a 3-year followup . J Urol. 159:1998;2013-2016.
11. Meyer F., Moore L., Bairati I., et al. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol. 162:1999;2024-2028.
12. Klotz L.H., Goldenberg L., Lewett M., et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy 36-month post-treatment PSA results . Urology. 53:1999;757-763.
13. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
14. Grossfeld G.D., Stier D.M., Flanders S.C., et al. Use of second treatment following definitive local therapy for prostate cancer data from the CaPSURE database . J Urol. 160:1998;1398-1404.
15. Labrie F., Cusan L., Gomez J.L., et al. Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol. 3:1999;217-226.
16. Akaza H., Homma Y., Okada K., et al. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naïve localized or locally advanced prostate cancer a prospective and randomized study: the Prostate Cancer Study Group . Jpn J Clin Oncol. 30:2000;131-136.
17. Leibowitz R., Tucker S.J. Treatment of localized prostate cancer with intermittent triple androgen blockade preliminary results in 110 consecutive patients . Oncologist. 6:2001;177-182.
18. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy results from the Prostate Cancer Outcomes Study . J Clin Oncol. 19:2001;3750-3757.
19. Lubeck D.P., Grossfeld G.D., Carroll P.R. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology. 58:2001;94-100.